Page 97 - Clinical Development News Today

Vivoryon Therapeutics is a precision medicine company focused on bringing first-in-class therapies to patients suffering from age-related diseases.

The US Food and Drug Administration (FDA) has today (July 31) given clearance via its 510(k) process to one of the artificial intelligence solutions cleared for colonoscopy.

/PRNewswire/ -- The "Emerging Landscape of Targeted Protein Degradation Therapeutics" report has been added to ResearchAndMarkets.coms offering. Advancing...

The company's shares rose on signs it might be getting closer to its first biologics license application.

Its revenues growing with business up 13% year-over-year, Labcorp reports a profit of $188.9 million in its second quarter. It's the first quarterly report where financials from the recently Fortrea spinoff were not included.

Research by Oregon State University used nanoparticles to deliver methotrexate, which worked at lower doses than are normally delivered.

Company Provides Full-Year Guidance Labcorp completed the spin-off of Fortrea on June 30, which is treated as discontinued operations in the historical...

The EMA organized a task force made up of various stakeholders to gather insights on potential EU-level actions to improve the set up of clinical trials during public health emergencies.

Further analysis shows that 300 mg lenacapvir tablets plus an optimized background regimen can effectively reconcile a missed dose of lenacapavir injection in patients with HIV.

Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team CAPE CANAVERAL, Fla., July 27,...